Therapies for necrotising fasciitis

Expert Opinion on Biological Therapy

Volumn 6, Issue 2, 2006, Pages 155-165

  Young, Michael H ^b   Engleberg, N Cary ^c   Mulla, Zuber D ^d,e   Aronoff, David M ^a  

^a UNIVERSITY OF MICHIGAN HOSPITALS   (United States)

^b ST JOSEPH MERCY HOSPITAL   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^e TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Antimicrobial therapy; Bacterial toxins; Clindamycin; Gangrene; Intravenous immunoglobulins; Necrotising fasciitis; Soft tissue infection; Streptococcus pyogenes; Superantigens; Toxic shock syndrome

Indexed keywords

ANTIBIOTIC AGENT; BETA LACTAM; BETA LACTAMASE; CEPHALOSPORIN; CLINDAMYCIN; ERTAPENEM; IMIPENEM; IMMUNOGLOBULIN; MEROPENEM; METRONIDAZOLE; PIPERACILLIN PLUS TAZOBACTAM; PROTEIN SYNTHESIS INHIBITOR; SULTAMICILLIN; TIMENTIN; VIRULENCE FACTOR;

CLINICAL FEATURE; DIAGNOSTIC IMAGING; DIAGNOSTIC TEST; HISTOPATHOLOGY; HUMAN; HYPERBARIC OXYGEN; LABORATORY TEST; MICROBIOLOGY; NECROTIZING FASCIITIS; PATHOGENESIS; REVIEW; RISK FACTOR; SOCIAL SUPPORT; STREPTOCOCCUS GROUP A; SYMPTOMATOLOGY; TREATMENT OUTCOME;

ANIMALS; FASCIITIS, NECROTIZING; HUMANS; HYPERBARIC OXYGENATION; IMMUNOGLOBULINS; IMMUNOGLOBULINS, INTRAVENOUS; MODELS, BIOLOGICAL; RISK FACTORS; VIRULENCE FACTORS;

BACTERIA (MICROORGANISMS); STREPTOCOCCUS GROUP A; STREPTOCOCCUS PYOGENES; STREPTOCOCCUS SP. 'GROUP A';

EID: 32944476047     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.6.2.155     Document Type: Review

References (119)

1. DESCAMPS V, AITKEN J, LEE MG: Hippocrates on necrotising fasciitis. Lancet (1994) 344(8921):556.
2. GREEN RJ, DAFOE DC, RAFFIN TA: Necrotizing fasciitis. Chest (1996) 110(1):219-229.
3. WILSON B: Necrotizing fasciitis. Am. Surg. (1952) 18(4):416-431.
4. GIULIANO A, LEWIS F JR, HADLEY K, BLAISDELL FW: Bacteriology of necrotizing fasciitis. Am. J. Surg. (1977) 134(1):52-57.
5. O'BRIEN KL, BEALL B, BARRETT NL et al.: Epidemiology of invasive group a streptococcus disease in the United States, 1995-1999. Clin. Infect. Dis. (2002) 35(3):268-276.
6. KAUL R, MCGEER A, LOW DE, GREEN K, SCHWARTZ B: Population-based surveillance for group A streptococcal necrotizing fasciitis: clinical features, prognostic indicators, and microbiologic analysis of seventy-seven cases. Ontario Group A Streptococcal Study. Am. J. Med. (1997) 103(1):18-24.
7. CHILDERS BJ, POTYONDY LD, NACHREINER R et al.: Necrotizing fasciitis: a fourteen-year retrospective study of 163 consecutive patients. Am. Surg. (2002) 68(2):109-116.
8. ELLIOTT D, KUFERA JA, MYERS RA: The microbiology of necrotizing soft tissue infections. Am. J. Surg. (2000) 179(5):361-366.
9. ELLIOTT DC, KUFERA JA, MYERS RA: Necrotizing soft tissue infections. Risk factors for mortality and strategies for management. Ann. Surg. (1996) 224(5):672-683.
10. MCHENRY CR, PIOTROWSKI JJ, PETRINIC D, MALANGONI MA: Determinants of mortality for necrotizing soft-tissue infections. Ann. Surg. (1995) 221(5):558-563; discussion 563-555.
11. WALL DB, KLEIN SR, BLACK S, DE VIRGILIO C: A simple model to help distinguish necrotizing fasciitis from nonnecrotizing soft tissue infection. J. Am. Coll. Surg. (2000) 191(3):227-231.
12. WONG CH, CHANG HC, PASUPATHY S et al.: Necrotizing fasciitis: clinical presentation, microbiology, and determinants of mortality. J. Bone Joint Surg. Am. (2003) 85-A(8):1454-1460.
13. WONG CH, KHIN LW, HENG KS, TAN KC, LOW CO: The LRINEC (Laboratory Risk Indicator for Necrotizing Fasciitis) score: a tool for distinguishing necrotizing fasciitis from other soft tissue infections. Crit. Care Med. (2004) 32(7):1535-1541.
14. SIMONART T, SIMONART JM, DERDELINCKX II et al.: Value of Standard laboratory tests for the early recognition of group A beta-hemolytic streptococcal necrotizing fasciitis. Clin. Infect. Dis. (2000) 32(1):E9-E12.
15. FACTOR SH: Invasive group A streptococcal disease: risk factors for adults. Emerg. Infect. Dis. (2003) 9(8):970-977.
16. LAUPLAND KB, DAVIES HD, LOW DE et al.: Invasive group A streptococcal disease in children and association with varicella-zoster virus infection. Ontario Group A Streptococcal Study Group. Pediatrics (2000) 105(5):E60.
17. FACTOR SH, LEVINE OS, HARRISON LH et al.: Risk factors for pediatric invasive group a streptococcal disease. Emerg. Infect. Dis. (2005) 11(7):1062-1066.
18. BRUN-BUISSON CJ, SAADA M, TRUNET P et al.: Haemolytic streptococcal gangrene and non-steroidal anti-inflammatory drugs. Br. Med. J. (Clin. Res. Ed.) (1985) 290(6484):1786.
19. ZERR DM, RUBENS CE: NSAIDS and necrotizing fasciitis. Pediatr. Infect. Dis. J. (1999) 18(8):724-725.
20. ARONOFF DM, BLOCH KC: Assessing the relationship between the use of nonsteroidal antiinflammatory drugs and necrotizing fasciitis caused by group A streptococcus. Medicine (Baltimore) (2003) 82(4):225-235.
21. HIRD B, BYRNE K: Gangrenous streptococcal myositis: case report. J. Trauma (1994) 36(4):589-591.
22. NICHOLS RL, FLORMAN S: Clinical presentations of soft-tissue infections and surgical site infections. Clin. Infect. Dis. (2001) 33(Suppl. 2):S84-S93.
23. ANDREASEN TJ, GREEN SD, CHILDERS BJ: Massive infectious soft-tissue injury: diagnosis and management of necrotizing fasciitis and purpura fulminans. Plast. Reconstr. Surg. (2001) 107(4):1025-1035.
24. YOUNG MH, ARONOFF DM, ENGLEBERG NC: Necrotizing fasciitis: pathogenesis and treatment. Expert Rev. Anti-Infect. Ther. (2005) 3(2):279-294.
25. GOMEZ JM, FAJARDO R, PATINO JF, ARIAS CA: Necrotizing fasciitis due to Vibrio alginolyticus in an immunocompetent patient. J. Clin. Microbiol. (2003) 41(7):3427-3429.
26. GOODELL KH, JORDAN MR, GRAHAM R, CASSIDY C, NASRAWAY SA: Rapidly advancing necrotizing fasciitis caused by Photobacterium (Vibrio) damsela: a hyperaggressive variant. Crit. Care Med. (2004) 32(1):278-281.
27. TSAI YH, HSU RW, HUANG KC et al.: Systemic Vibrio infection presenting as necrotizing fasciitis and sepsis. A series of thirteen cases. J. Bone Joint Surg. Am. (2004) 86-A(11):2497-2502.
28. MILLER LG, PERDREAU-REMINGTON F, RIEG G et al.: Necrotizing fasciitis caused by community-associated methicillin-resistant Staphylococcus aureus in Los Angeles. N. Engl. J. Med. (2005) 352(14):1445-1453.
29. MICEK ST, DUNNE M, KOLLEF MH: Pleuropulmonary complications of Panton-Valentine leukocidin-positive community-acquired methicillin-resistant Staphylococcus aureus: importance of treatment with antimicrobials inhibiting exotoxin production. Chest (2005) 128(4):2732-2738.
30. MILXER LG, PERDEAU-REMINGTON F, MEHDI S et al.: Fourteen cases with necrotizing fasciitis caused by community-onset MRSA in Los Angeles. 42nd Annual Meetin of IDSA. Boston, MA, USA (30 September - 3 October 2004).
31. DIEP BA, SENSABAUGH GF, SOMBOONA NS, CARLETON HA, PERDREAU-REMINGTON F: Widespread skin and soft-tissue infections due to two methicillin-resistant Staphylococcus aureus strains harboring the genes for Panton-Valentine leucocidin. J. Clin. Microbiol. (2004) 42(5):2080-2084.
32. DAHL PR, PERNICIARO C, HOLMKVIST KA, O'CONNOR MI, GIBSON LE: Fulminant group A streptococcal necrotizing fasciitis: clinical and pathologic findings in 7 patients. J. Am. Acad. Dermatol. (2002) 47(4):489-492.
33. DELLINGER EP: Severe necrotizing soft-tissue infections. Multiple disease entities requiring a common approach. JAMA (1981) 246(15):1717-1721.
34. HITE K, LOCKE M, HESSELTINE H: Synergism in experimental infections with nonsporulating anaerobic bacteria. J Infect. Dis. (1949) 84:1.
35. ROBERTS DS: The pathogenic synergy of Fusiformis necrophorus and Corynebacterium pyogenes. I. Influence of the leucocidal exotoxin of F. necrophorus. Br. J. Exp. Pathol. (1967) 48(6):665-673.
36. ROBERTS DS: Synergic mechanisms in certain mixed infections. J. Infect. Dis. (1969) 120(6):720-724.
37. BISNO AL, BRITO MO, COLLINS CM: Molecular basis of group A streptococcal virulence. Lancet Infect. Dis. (2003) 3(4):191-200.
38. CUNNINGHAM MW: Pathogenesis of group A streptococcal infections. Clin. Microbiol. Rev. (2000) 13(3):470-511.
39. HO PL, JOHNSON DR, YUE AW et al.: Epidemiologic analysis of invasive and noninvasive group a streptococcal isolates in Hong Kong. J. Clin. Microbiol. (2003) 41(3):937-942.
40. MYLVAGANAM H, BJORVATN B, OSLAND A: Distribution and sequence variations of selected virulence genes among group A streptococcal isolates from western Norway. APMIS (2000) 108(11):771-778.
41. MYLVAGANAM H, BJORVATN B, HOFSTAD T, OSLAND A: Emm gene polymorphism among temporally clustered group A streptococcal isolates in western Norway. APMIS (2000) 108(4):303-312.
42. ZURAWSKI CA, BARDSLEY M, BEALL B et al.: Invasive group A streptococcal disease in metropolitan Atlanta: a population-based assessment. Clin. Infect. Dis. (1998) 27(1):150-157.
43. COCKERILL FR 3RD, THOMPSON RL, MUSSER JM et al.: Molecular, serological, and clinical features of 16 consecutive cases of invasive streptococcal disease. Southeastern Minnesota Streptococcal Working Group. Clin. Infect. Dis. (1998) 26(6):1448-1458.
44. SUN H, RINGDAHL U, HOMEISTER JW et al.: Plasminogen is a critical host pathogenicity factor for group A streptococcal infection. Science (2004) 305(5688):1283-1286.
45. WALKER MJ, MCARTHUR JD, MCKAY F, RANSON M: Is plasminogen deployed as a Streptococcus pyogenes virulence factor? Trends Microbiol. (2005) 13(7):308-313.
46. ENGLEBERG NC, HEATH A, VARDAMAN K, DIRITA VJ: Contribution of CsrR-regulated virulence factors to the progress and outcome of murine skin infections by Streptococcus pyogenes. Infect. Immun. (2004) 72(2):623-628.
47. DARENBERG J, IHENDYANE N, SJOLIN J et al.: Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: a European randomized, double-blind, placebo-controlled trial. Clin. Infect. Dis. (2003) 37(3):333-340.
48. STEVENS DL, TANNER MH, WINSHIP J et al.: Severe group A streptococcal infections associated with a toxic shock-like syndrome and scarlet fever toxin A. N. Engl. J. Med. (1989) 321(1):1-7.
49. NORRBY-TEGLUND A, THULIN P, GAN BS et al.: Evidence for superantigen involvement in severe group a streptococcal tissue infections. J. Infect. Dis. (2001) 184(7):853-860.
50. LEVIN JC, WESSELS MR: Identification of csrR/csrS, a genetic locus that regulates hyaluronic acid capsule synthesis in group A Streptococcus. Mol. Microbiol. (1998) 30(1):209-219.
51. GRAHAM MR, SMOOT LM, MIGLIACCIO CA et al.: Virulence control in group A Streptococcus by a two-component gene regulatory system: global expression profiling and in vivo infection modeling. Proc. Natl. Acad. Sci. USA (2002) 99(21):13855-13860.
52. VOYICH JM, MUSSER JM, DELEO FR: Streptococcus pyogenes and human neutrophils: a paradigm for evasion of innate host defense by bacterial pathogens. Microbes Infect. (2004) 6(12):1117-1123.
53. MUSSER JM, KAPUR V, SZETO J et al.: Genetic diversity and relationships among Streptococcus pyogenes strains expressing serotype M1 protein: recent intercontinental spread of a subclone causing episodes of invasive disease. Inject. Immun. (1995) 63(3):994-1003.
54. KOTB M, NORRBY-TEGLUND A, MCGEER A et al.: An immunogenetic and molecular basis for differences in outcomes of invasive group A streptococcal infections. Nat. Med. (2002) 8(12):1398-1404.
55. NORRBY-TEGLUND A, CHATELLIER S, LOW DE et al.: Host variation in cytokine responses to superantigens determine the severity of invasive group A streptococcal infection. Eur. J. Immunol. (2000) 30(11):3247-3255.
56. KOTB M, NORRBY-TEGLUND A, MCGEER A, GREEN K, LOW DE: Association of human leukocyte antigen with outcomes of infectious diseases: the streptococcal experience. Scand. J. Infect. Dis. (2003) 35(9):665-669.
57. SRISKANDAN S, UNNIKRISHNAN M, KRAUSZ T et al.: Enhanced susceptibility to superantigen-associated streptococcal sepsis in human leukocyte antigen-DQ transgenic mice. J. Infect. Dis. (2001) 184(2):166-173.
58. LUNGSTRAS-BUFLER K, BUFLER P, ABDULLAH R et al.: High cytokine levels at admission are associated with fatal outcome in patients with necrotizing fasciitis. Eur. Cytokine Netw. (2004) 15(2):135-138.
59. BASMA H, NORRBY-TEGLUND A, GUEDEZ Y et al.: Risk factors in the pathogenesis of invasive group A streptococcal infections: role of protective humoral immunity. Infect. Immun. (1999) 67(4):1871-1877.
60. MASCINI E, HAZENBERG M: Invasive group A streptococcal disease, association with a lack of anti-exotoxin antibodies. In: Streptococci and the Host. Horaud T, Bouvet A, Leclercq R, de Montclos H, Sicard M (Eds), Plenum Press, New York, USA (1997).
61. NORRBY-TEGLUND A, PAUKSENS K, HOLM SE, NORGREN M: Relation between low capacity of human sera to inhibit streptococcal mitogens and serious manifestation of disease. J Infect. Dis. (1994) 170(3):585-591.
62. WONG CH, WANG YS: The diagnosis of necrotizing fasciitis. Curr. Opin. Infect. Dis. (2005) 18(2):101-106.
63. BISNO AL, COCKERILL FR 3RD, BERMUDEZ CT: The initial outpatient-physician encounter in group A streptococcal necrotizing fasciitis. Clin. Infect. Dis. (2000) 31(2):607-608.
64. MULLA ZD: Group A streptococcal necrotizing fasciitis: Reducing the risk of unwarranted litigation. Am. J. Emerg. Med. (2005) 23(4):578-579.
65. HAYWOOD CT, MCGEER A, LOW DE: Clinical experience with 20 cases of group A streptococcus necrotizing fasciitis and myonecrosis: 1995 to 1997. Plast. Reconstr. Surg. (1999) 103(6):1567-1573.
66. SCHIODT M: Deep cervical infections - an uncommon but significant problem. Oral Dis. (2002) 8(4):180-182.
67. MELENEY F: Hemolytic streptococcal gangrene. Arch. Surg. (1924) (9):317-614.
68. TILLOU A, ST HILL CR, BROWN C, VELMAHOS G: Necrotizing soft tissue infections: improved outcomes with modern care. Am. Surg. (2004) 70(10):841-844.
69. FISHER JR, CONWAY MJ, TAKESHITA RT, SANDOVAL MR: Necrotizing fasciitis. Importance of roentgenographic studies for soft-tissue gas. JAMA (1979) 241(8):803-806.
70. WYSOKI MG, SANTORA TA, SHAH RM, FRIEDMAN AC: Necrotizing fasciitis: CT characteristics. Radiology (1997) 203(3):859-863.
71. BROTHERS TE, TAGGE DU, STUTLEY JE et al.: Magnetic resonance imaging differentiates between necrotizing and non-necrotizing fasciitis of the lower extremity. J. Am. Coll. Surg. (1998) 187(4):416-421.
72. LOH NN, CH'EN IY, CHEUNG LP, LI KC: Deep fascial hyperintensity in soft-tissue abnormalities as revealed by T2-weighted MR imaging. AJR Am. J. Roentgenol. (1997) 168(5):1301-1304.
73. RAHMOUNI A, CHOSIDOW O, MATHIEU D et al.: MR imaging in acute infectious cellulitis. Radiology (1994) 192(2):493-496.
74. SCHMID MR, KOSSMANN T, DUEWELL S: Differentiation of necrotizing fasciitis and cellulitis using MR imaging. AJR Am. J. Roentgenol. (1998) 170(3):615-620.
75. MAJESKI J, MAJESKI E: Necrotizing fasciitis: improved survival with early recognition by tissue biopsy and aggressive surgical treatment. South. Med. J. (1997) 90(11):1065-1068.
76. STAMENKOVIC I, LEW PD: Early recognition of potentially fatal necrotizing fasciitis. The use of frozen-section biopsy. N. Engl. J. Med. (1984) 310(26):1689-1693.
77. WANG TL, HUNG CR: Role of tissue oxygen saturation monitoring in diagnosing necrotizing fasciitis of the lower limbs. Ann. Emerg. Med. (2004) 44(3):222-228.
78. MAJESKI JA, ALEXANDER JW: Early diagnosis, nutritional support, and immediate extensive debridement improve survival in necrotizing fasciitis. Am. J. Surg. (1983) 145(6):784-787.
79. VOROS D, PISSIOTIS C, GEORGANTAS D et al.: Role of early and extensive surgery in the treatment of severe necrotizing soft tissue infection. Br. J. Surg. (1993) 80(9):1190-1191.
80. WARD RG: Necrotising fasciitis. Immediate surgical opinion is essential. Br. Med. J. (1994) 309(6950):341.
81. DE GEUS HR, VAN DER KLOOSTER JM: Vacuum-assisted closure in the treatment of large skin defects due to necrotizing fasciitis. Intensive Care Med. (2005) 31(4):601.
82. OCZENSKI W, WALDENBERGER F, NEHRER G et al.: Vacuum-assisted closure for the treatment of cervical and mediastinal necrotizing fasciitis. J. Cardiothorac. Vasc. Anesth. (2004) 18(3):336-338.
83. COYLE EA: Targeting bacterial virulence: the role of protein synthesis inhibitors in severe infections. Insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy (2003) 23(5):638-642.
84. COYLE EA, CHA R, RYBAK MJ: Influences of linezolid, penicillin, and clindamycin, alone and in combination, on streptococcal pyrogenic exotoxin a release. Antimicrob. Agents Chemother. (2003) 47(5):1752-1755.
85. MULLA ZD: Treatment options in the management of necrotising fasciitis caused by Group A Streptococcus. Expert Opin. Pharmacother. (2004) 5(8):1695-1700.
86. HIRATA N, HIRAMATSU K, KISHI K et al.: Pretreatment of mice with clindamycin improves survival of endotoxic shock by modulating the release of inflammatory cytokines. Antimicrob. Agents Chemother. (2001) 45(9):2638-2642,
87. NAKANO T, HIRAMATSU K, KISHI K et al.: Clindamycin modulates inflammatory-cytokine induction in lipopolysaccharide-stimulated mouse peritoneal macrophages. Antimicrob. Agents Chemother. (2003) 47(1):363-367.
88. STEVENS DL, BRYANT AE, HACKETT SP: Antibiotic effects on bacterial viability, toxin production, and host response. Clin. Infect. Dis. (1995) 20(Suppl. 2):S154-S157.
89. EAGLE H: Experimental approach to the problem of treatment failure with penicillin. I. Group A streptococcal infection in mice. Am. J. Med. (1952) (13):389-389.
90. STEVENS DL, GIBBONS AE, BERGSTROM R, WINN V: The Eagle effect revisited: efficacy of clindamycin, erythromycin, and penicillin in the treatment of streptococcal myositis. J. Infect. Dis. (1988) 158(1):23-28.
91. ZIMBELMAN J, PALMER A, TODD J: Improved outcome of clindamycin compared with beta-lactam antibiotic treatment for invasive Streptococcus pyogenes infection. Pediatr. Infect. Dis. J. (1999) 18(12):1096-1100.
92. GRAVES C, SAFFLE J, MORRIS S, STAUFFER T, EDELMAN L: Caloric requirements in patients with necrotizing fasciitis. Burns (2005) 31(1):55-59.
93. CAWLEY MJ, BRIGGS M, HAITH LR JR et al.: Intravenous immunoglobulin as adjunctive treatment for streptococcal toxic shock syndrome associated with necrotizing fasciitis: case report and review. Pharmacotherapy (1999) 19(9):1094-1098.
94. KAUL R, MCGEER A, NORRBY-TEGLUND A et al.: Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome - a comparative observational study. The Canadian Streptococcal Study Group. Clin. Infect. Dis. (1999) 28(4):800-807.
95. NORRBY-TEGLUND A, IHENDYANE N, DARENBERG J: Intravenous immunoglobulin adjunctive therapy in sepsis, with special emphasis on severe invasive group A streptococcal infections. Scand. J. Infect. Dis. (2003) 35(9):683-689.
96. NORRBY-TEGLUND A, MULLER MP, MCGEER A et al.: Successful management of severe group A streptococcal soft tissue infections using an aggressive medical regimen including intravenous polyspecific immunoglobulin together with a conservative surgical approach. Scand. J. Infect. Dis. (2005) 37(3):166-172.
97. PATEL R, ROUSE MS, FLOREZ MV et al.: Lack of benefit of intravenous immune globulin in a murine model of group A streptococcal necrotizing fasciitis. J Infect. Dis. (2000) 181(1):230-234.
98. JALLALI N, WITHEY S, BUTLER PE: Hyperbaric oxygen as adjuvant therapy in the management of necrotizing fasciitis. Am. J. Surg. (2005) 189(4):462-466.
99. KINDWALL EP: Uses of hyperbaric oxygen therapy in the 1990s. Cleve. Clin. J. Med. (1992) 59(5):517-528.
100. NACHREINER R, CHILDERS B, KIZZAR R, HARDESTY RA, LO T: Adjunctive hyperbaric oxygen therapy for necrotizing fasciitis: a 10-year experience. Plast. Surg. Forum (1995) 18:334-335.
101. RISEMAN JA, ZAMBONI WA, CURTIS A et al.: Hyperbaric oxygen therapy for necrotizing fasciitis reduces mortality and the need for debridements. Surgery (1990) 108(5):847-850.
102. DEMELLO FJ, HAGLIN JJ, HITCHCOCK CR: Comparative study of experimental Clostridium perfringens infection in dogs treated with antibiotics, surgery, and hyperbaric oxygen. Surgery (1973) 73(6):936.
103. ARAD G, HILLMAN D, LEVY R, KAEMPFER R: Broad-spectrum immunity against superantigens is elicited in mice protected from lethal shock by a superantigen antagonist peptide. Immunol. Lett. (2004) 91(2-3):141-145.
104. ARAD G, HILLMAN D, LEVY R, KAEMPFER R: Superantigen antagonist blocks Th1 cytokine gene induction and lethal shock. J. Leukoc. Biol. (2001) 69(6):921-927.
105. ARAD G, LEVY R, HILLMAN D, KAEMPFER R: Superantigen antagonist protects against lethal shock and defines a new domain for T-cell activation. Nat. Med. (2000) 6(4):414-421.
106. HALL MA, STROOP SD, HU MC et al.: Intranasal immunization with multivalent group A streptococcal vaccines protects mice against intranasal challenge infections. Infect. Immun. (2004) 72(5):2507-2512.
107. KOTLOFF KL, CORRETTI M, PALMER K et al.: Safety and immunogenicity of a recombinant multivalent group a streptococcal vaccine in healthy adults: Phase I trial. JAMA (2004) 292(6):709-715.
108. DALE JB, CHIANG EY, HASTY DL, COURTNEY HS: Antibodies against a synthetic peptide of SagA neutralize the cytolytic activity of streptolysin S from group A streptococci. Infect. Immun. (2002) 70(4):2166-2170.
109. MCCORMICK JK, TRIPP TJ, OLMSTED SB et al.: Development of streptococcal pyrogenic exotoxin C vaccine toxoids that are protective in the rabbit model of toxic shock syndrome. J. Immunol. (2000) 165(4):2306-2312.
110. ROGGIANI M, STOEHR JA, OLMSTED SB et al.: Toxoids of streptococcal pyrogenic exotoxin A are protective in rabbit models of streptococcal toxic shock syndrome. Infect. Immun. (2000) 68(9):5011-5017.
111. BERNARD GR, VINCENT JL, LATERRE PF et al.: Efficacy and safety of recombinant human activated protein C for severe sepsis. N. Engl. J. Med. (2001) 344(10):699-709.
112. COLMAN RW, SCHMAIER AH: Contact system: a vascular biology modulator with anticoagulant, profibrinolytic, antiadhesive, and proinflammatory attributes. Blood (1997) 90(10):3819-3843.
113. COLE L, BELLOMO R, JOURNOIS D et al.: High-volume haemofiltration in human septic shock. Intensive Care Med. (2001) 27(6):978-986.
114. FENWICK P, RYAN C, SRISKANDAN S, COHEN J: Application of a rat model of streptococcal shock to evaluate on-line hemoperfusion and removal of circulating superantigens. Crit. Care Med. (2003) 31(1):171-178.
115. RONCO C, INGUAGGIATO P, D'INTINI V et al.: The role of extracorporeal therapies in sepsis. J. Nephrol. (2003) 16(Suppl. 7):S34-S41.
116. STEGMAYR BG: Apheresis as therapy for patients with severe sepsis and multiorgan dysfunction syndrome. Ther. Apher. (2001) 5(2):123-127.
117. STEGMAYR BG: The presence of superantigens and complex host responses in severe sepsis may need a broad therapeutic approach. Ther. Apher. (2001) 5(2):111-114.
118. MULLA ZD, LEAVERTON PE, WIERSMA ST: Invasive group A streptococcal infections in Florida. South. Med. J. (2003) 96(10):968-973.
119. WALL DB, DE VIRGILIO C, BLACK S, KLEIN SR: Objective criteria may assist in distinguishing necrotizing fasciitis from nonnecrotizing soft tissue infection. Am. J. Surg. (2000) 179(1):17-21.